Biodesix Announces Breakthroughs on VeriStrat Test at ASCO
Biodesix, Inc. has announced exciting new data regarding their innovative VeriStrat test, which will be shared during the prestigious American Society of Clinical Oncology (ASCO) Annual Meeting. This vital presentation is scheduled to commence at 2:30 PM ET on Saturday and features groundbreaking research pertaining to patients with non-small cell lung cancer (NSCLC).
The Significance of the VeriStrat Test
The VeriStrat test is designed to evaluate the immune response of patients to lung cancer by categorizing them as either Host Immune Classifier Hot or Cold. Those classified as Hot are considered to have a more favorable response, known as VeriStrat Good, while those classified as Cold experience a poorer response, referred to as VeriStrat Poor. With fresh insights from the INSIGHT study, which involved over 5,000 NSCLC patients, new findings reveal a significant leap in overall survival for those with VeriStrat Poor results when treated with a combination of immunotherapy and chemotherapy.
Impressively Improved Survival Rates
Data highlights a crucial breakthrough: patients exhibiting a VeriStrat Poor classification who underwent combined treatment have demonstrated more than triple the two-year survival rate compared to those who were treated with immunotherapy alone. Interestingly, patients identified as VeriStrat Good displayed similar survival rates, regardless of the treatment approach.
Expert Insights on Treatment Implications
Dr. Gary Pestano, Chief Development Officer at Biodesix, shed light on the implications of these findings: "Immunotherapy remains a beacon of hope in cancer treatments; however, responses vary among patients. Our recent findings imply that the VeriStrat test could become a pivotal tool for oncologists. It can aid in assessing treatment implications, allowing for more tailored approaches that could ultimately elevate patient care standards and outcomes."
Broader Applications of the VeriStrat Test
In addition to its efficacy in lung cancer cases, preliminary results from another ongoing study suggest the VeriStrat test's utility may extend to patients with a variety of solid tumors. This exciting potential could pave the way for improved patient stratification and targeted therapy across multiple cancer types, with further definitive data set to be published in the near future.
About Biodesix
Biodesix, Inc., a leading name in diagnostic solutions, is committed to enhancing clinical care and patient outcomes. Their offerings, including the Nodify Lung® Nodule Risk Assessment and IQLung™ Cancer Treatment Guidance tests, are crucial in helping clinicians make informed decisions regarding personalized treatment pathways for patients suffering from lung disease. Their development services empower biopharmaceutical and life sciences institutions with the necessary scientific, technological, and operational support to elevate the diagnostic landscape.
Connect with Biodesix
For media inquiries, contact Natalie St. Denis, Director of Corporate Communications at Biodesix, via natalie.stdenis@biodesix.com or call (720) 925-9285. Investor contact can be directed to Chris Brinzey, Partner at ICR Healthcare at chris.brinzey@icrhealthcare.com, or reach out at (339) 970-2843.
Frequently Asked Questions
What is the VeriStrat test used for?
The VeriStrat test assesses a patient's immune response to lung cancer, which aids in predicting treatment outcomes.
How does the combined therapy improve patient survival?
Patients with VeriStrat Poor results experienced a significant increase in overall survival when treated with immunotherapy alongside chemotherapy.
What new findings were announced by Biodesix?
Biodesix unveiled data showing improved survival rates for NSCLC patients receiving combined immunotherapy and chemotherapy, with insights presented at ASCO.
Who presented the research at the ASCO Annual Meeting?
Dr. Vamsidhar Velcheti, MD, Director of Thoracic Oncology at NYU Langone, presented the findings from the INSIGHT study.
What other applications could VeriStrat have?
Preliminary indications suggest that the VeriStrat test may also be useful for guiding treatment in various types of solid tumors beyond lung cancer.
